Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Free Cash Flow: 2009-2025

Historic Free Cash Flow for Gyre Therapeutics (GYRE) over the last 16 years, with Sep 2025 value amounting to $4.0 million.

  • Gyre Therapeutics' Free Cash Flow rose 284.03% to $4.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 million, marking a year-over-year increase of 230.04%. This contributed to the annual value of -$6.0 million for FY2024, which is 134.28% down from last year.
  • Latest data reveals that Gyre Therapeutics reported Free Cash Flow of $4.0 million as of Q3 2025, which was up 111.80% from $1.9 million recorded in Q2 2025.
  • In the past 5 years, Gyre Therapeutics' Free Cash Flow ranged from a high of $42.3 million in Q4 2022 and a low of -$24.4 million during Q1 2021.
  • Over the past 3 years, Gyre Therapeutics' median Free Cash Flow value was $1.9 million (recorded in 2025), while the average stood at $1.5 million.
  • Its Free Cash Flow has fluctuated over the past 5 years, first surged by 339.30% in 2022, then tumbled by 437.99% in 2024.
  • Over the past 5 years, Gyre Therapeutics' Free Cash Flow (Quarterly) stood at -$17.7 million in 2021, then surged by 339.30% to $42.3 million in 2022, then crashed by 97.55% to $1.0 million in 2023, then crashed by 359.94% to -$2.7 million in 2024, then soared by 284.03% to $4.0 million in 2025.
  • Its last three reported values are $4.0 million in Q3 2025, $1.9 million for Q2 2025, and -$251,000 during Q1 2025.